Accessibility Menu
Liminatus Pharma logo

Liminatus Pharma

(NASDAQ) LIMN

Current Price$0.13
Market Cap$5.48M
Since IPO (2021)-99%
5 YearN/A
1 Year-99%
1 Month-34%

Liminatus Pharma Financials at a Glance

Market Cap

$5.48M

Revenue (TTM)

$0.00

Net Income (TTM)

-$11.00M

EPS (TTM)

-$0.40

P/E Ratio

-0.31

Dividend

$0.00

Beta (Volatility)

1.06 (Average)

Price

$0.13

Volume

2,551,218.962

Open

$0.14

Previous Close

$0.12

Daily Range

$0.12 - $0.14

52-Week Range

$0.12 - $33.66

Estimated Earnings Date

May 15, 2026

LIMN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Liminatus Pharma

Industry

Biotechnology

Sector

Health Care

Employees

1

CEO

Chris Kim

Website

liminatuspharma.com

Headquarters

La Palma, CA 90623, US

LIMN Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

0%

Return on Capital

38%

Return on Assets

-4%

Earnings Yield

-3.23%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.48M

Shares Outstanding

44.88M

Volume

2.55M

Avg. Volume

10.01M

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$2.97M

EBITDA

-$9.99M

Operating Cash Flow

-$9.96M

Capital Expenditure

-$13.11K

Free Cash Flow

-$9.98M

Cash & ST Invst.

$337.66K

Total Debt

$1.44M

Liminatus Pharma Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$518.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$5.48M

N/A

Market Cap/Employee

$1.83M

N/A

Employees

3

N/A

Net Income

-$1.12M

-440572.2%

EBITDA

-$1.11M

-1058.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.91M

N/A

Total Debt

$1.44M

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$1.44M

N/A

Return on Assets

-3.94%

N/A

Return on Invested Capital

38.36%

N/A

Free Cash Flow

-$2.02M

N/A

Operating Cash Flow

-$2.02M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
JSPRJasper Therapeutics, Inc.
$0.46-1.80%
EVAXEvaxion Biotech A/S
$3.64+0.83%
DYAIDyadic International, Inc.
$0.68-0.04%
SABSSAB Biotherapeutics, Inc.
$3.33-1.48%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$14.98+0.02%
NOKNokia
$14.80+0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.59+0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$77.52+0.02%

Questions About LIMN

What is the current price of Liminatus Pharma?

Liminatus Pharma is trading at $0.12 per share.

What is the 52-week range for Liminatus Pharma?

Over the past 52 weeks, Liminatus Pharma has traded between $0.12 and $33.66.

How much debt does Liminatus Pharma have?

As of the most recent reporting period, Liminatus Pharma reported total debt of $1.44M.

How much cash does Liminatus Pharma have on hand?

Liminatus Pharma reported $1.91M in cash and cash equivalents in its most recent financial results.

What is Liminatus Pharma’s dividend yield?

Liminatus Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services